Beam Therapeutics, Bio Palette Ink Exclusive License Agreements for Base Editing Technologies.
M2 PHARMA-May 31, 2019-Beam Therapeutics, Bio Palette Ink Exclusive License Agreements for Base Editing Technologies
(C)2019 M2 COMMUNICATIONS
- US-based biotechnology company Beam Therapeutics and Japan-based biotechnology companyBio Palette have inked an exclusive cross-license agreement around each companies' base editing intellectual property, the companies said.
Bio Palette, a Japanese biotechnology company, is developing new genome editing technologies for use in various fields, including agriculture and the microbiome. Bio Palette has licensed base editing intellectual property from Kobe University, which was invented by Drs. Keiji Nishida and Akihiko Kondo.
Beam Therapeutics, a US-based biotechnology company, is developing precision genetic medicines through base editing. Beam has licensed its foundational base editing intellectual property from Harvard University, the Broad Institute, MIT and Editas Medicine across multiple base editing platforms.
Under the terms of its agreement with Beam, Bio Palette is granting Beam an exclusive license to develop Bio Palette's intellectual property in the field of human therapeutics, with the exception of rights to microbiome related therapeutics in Asia, which are retained by Bio Palette.
In addition, Beam is granting Bio Palette an exclusive license to IP from its foundational license agreements to develop microbiome-related therapeutics in Asia. In order to strengthen the competitive position of both Parties, the Parties intend to work together to leverage Bio Palette's experience and expertise in Japan.
Bio Palette agrees to assist Beam in developing relationships in Japan, and to advise on Beam's business development strategy in Japan.
Financial terms of the agreement include an undisclosed upfront payment to Bio Palette from Beam, an equity position in Beam by Bio Palette, and royalties from sales of commercialized products by Beam or Bio Palette to the other party.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||May 31, 2019|
|Previous Article:||Axial Biotherapeutics Publishes Preclinical Data Highlighting the Link Between Human Gut Microbiota and Behavioral Symptoms of Autism Spectrum...|
|Next Article:||4D Molecular Therapeutics Presents Preclinical Data at the 6th International Update on Fabry Disease and Provides Clinical Update.|